CN111568925A - Eye drop formula and preparation method thereof - Google Patents
Eye drop formula and preparation method thereof Download PDFInfo
- Publication number
- CN111568925A CN111568925A CN202010393483.1A CN202010393483A CN111568925A CN 111568925 A CN111568925 A CN 111568925A CN 202010393483 A CN202010393483 A CN 202010393483A CN 111568925 A CN111568925 A CN 111568925A
- Authority
- CN
- China
- Prior art keywords
- parts
- chloramphenicol
- hertz
- functional water
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an eye drop formula which comprises the following raw materials in parts by weight: 0.5-0.9 part of chloramphenicol, 0.2-0.3 part of naphazoline hydrochloride, 0.3-0.8 part of triamcinolone acetonide acetate and 7000-8000 parts of hertz functional water; the formula comprises the following raw materials in parts by weight: 0.8 part of chloramphenicol, 0.25 part of naphazoline hydrochloride, 0.5 part of triamcinolone acetonide acetate and 7500 parts of Hertz functional water. A method for preparing an eye drop containing the formula comprises the following steps: firstly, mixing the chloramphenicol and the naphazoline hydrochloride according to the formula ratio, adding the Hertz functional water, uniformly stirring, adding the triamcinolone acetonide acetate, fully and uniformly mixing, and packaging and sealing by using a high-temperature disinfection bottle for later use. The invention can be used for treating various eye discomfort, and has special effects on turbid glass, slight cataract, keratitis, pinkeye, eye diseases caused by electric welding injury, dry eyes or itching eyes, and the like.
Description
Technical Field
The invention relates to the technical field of eye drop formulas, in particular to an eye drop formula and a preparation method thereof.
Background
The diseases of eyes are quite common diseases, the main causes are each part of the eyes, after the vision deterioration of different degrees is changed, the fiber of the eyeball is destroyed under the action of external factors, thereby generating a series of clinical symptoms such as eye pain, vitreous opacity, slight cataract, eye keratitis, pinkeye, electric welding eyes, dry eyes, eye itch and the like.
Eye pain is the most common symptom in most patients with eye diseases, and the incidence rate is more than nine times. In severe cases, the pain is aggravated, the pain of the patient is very painful, and the physical and mental health and the normal life of the patient are seriously affected.
The existing eye drops are mostly composed of western medicine components, and different eye drops have respective purposes, such as treating eye infection, reducing intraocular pressure, diminishing inflammation and relieving pain or relieving eye dryness. Many eye drops, like other drugs, have varying degrees of side effects. With the development of technology in recent years, some traditional Chinese medicine formula eye drops are developed, mostly have the efficacies of dispelling wind, clearing heat and improving eyesight, have single function and only aim at one disease.
Disclosure of Invention
In order to solve the existing problems, the invention provides an eye drop formula and a preparation method thereof. The invention is realized by the following technical scheme.
An eye drop formula comprises the following raw materials in parts by weight: 0.5-0.9 part of chloramphenicol, 0.2-0.3 part of naphazoline hydrochloride, 0.3-0.8 part of triamcinolone acetonide acetate and 7000-8000 parts of hertz functional water.
Preferably, the formula comprises the following raw materials in parts by weight: 0.7-0.9 part of chloramphenicol, 0.2-0.3 part of naphazoline hydrochloride, 0.4-0.6 part of triamcinolone acetonide acetate and 7000-7500 parts of hertz functional water.
Preferably, the formula comprises the following raw materials in parts by weight: 0.8 part of chloramphenicol, 0.25 part of naphazoline hydrochloride, 0.5 part of triamcinolone acetonide acetate and 7500 parts of Hertz functional water.
A method for preparing an eye drop containing the formula comprises the following steps: firstly, mixing the chloramphenicol and the naphazoline hydrochloride according to the formula ratio, adding the Hertz functional water, uniformly stirring, adding the triamcinolone acetonide acetate, fully and uniformly mixing, and packaging and sealing by using a high-temperature disinfection bottle for later use.
The invention has the beneficial effects that:
the eye drop formula and the preparation method thereof adopt chloramphenicol, naphazoline hydrochloride, triamcinolone acetonide acetate and Hertz functional water as raw materials to prepare the eye drop, have simple preparation method, are proved, have no toxic or side effect and obvious effect, can be used for various eye discomforts, and have special effects on turbid glass, slight cataract, keratitis, pinkeye, eye diseases caused by electric welding, dry eyes or itching eyes and the like.
Detailed Description
The technical solution of the present invention will be described in more detail and fully with reference to the following embodiments.
Example 1
An eye drop formula comprises 0.8mg of chloramphenicol, 0.25mg of naphazoline hydrochloride, 0.5mg of triamcinolone acetonide acetate and 7500mg of Hertz functional water, wherein the eye drop formula adopts the functional water of a box made of a trinuclear new dynamic health preserving cup.
A method for preparing an eye drop containing the formula comprises the following steps: firstly, mixing the chloramphenicol and the naphazoline hydrochloride according to the formula ratio, adding the trinuclear Hertz functional water, uniformly stirring, adding the triamcinolone acetonide acetate, fully and uniformly mixing, and packaging and sealing by using a high-temperature disinfection bottle for later use.
The using method comprises the following steps: one to two drops were applied to each eye twice a day.
Example 2
An eye drop formula comprises 0.9mg of chloramphenicol, 0.3mg of naphazoline hydrochloride, 0.4mg of triamcinolone acetonide acetate and 8000mg of Hertz functional water, wherein the eye drop formula adopts the functional water of a box made of a trinuclear new dynamic health preserving cup.
A method for preparing an eye drop containing the formula comprises the following steps: firstly, mixing the chloramphenicol and the naphazoline hydrochloride according to the formula ratio, adding the trinuclear Hertz functional water, uniformly stirring, adding the triamcinolone acetonide acetate, fully and uniformly mixing, and packaging and sealing by using a high-temperature disinfection bottle for later use.
The using method comprises the following steps: one to two drops were applied to each eye twice a day.
Example 3
An eye drop formula comprises 0.5mg of chloramphenicol, 0.3mg of naphazoline hydrochloride, 0.8mg of triamcinolone acetonide acetate and 7500mg of Hertz functional water, wherein the eye drop formula adopts the functional water of a box made of a trinuclear new dynamic health preserving cup.
A method for preparing an eye drop containing the formula comprises the following steps: firstly, mixing the chloramphenicol and the naphazoline hydrochloride according to the formula ratio, adding the trinuclear Hertz functional water, uniformly stirring, adding the triamcinolone acetonide acetate, fully and uniformly mixing, and packaging and sealing by using a high-temperature disinfection bottle for later use.
The using method comprises the following steps: one to two drops were applied to each eye twice a day.
Through test comparison, the proportioning effect of the concrete example 1 is best.
The following describes typical cases of several practical examples 1.
1, medical record: the eye drop is dripped once every day and two drops are dripped for one eye each time; eyes are not dry and itchy for three days, and visual objects are clear.
And (3) medical record 2: wangzhi, male, age 50, keratitis, doctor advised to do surgery. After the eye drop is used, the inflammation disappears after three days, the symptoms disappear after five days, and the eyes recover.
Case 3, Liji, male, age 54, blurred vision, dry eyes, itchy eyes due to diabetes syndrome. After the eye drop is used for one week, eyes recover to be normal.
Case 4, Sunzhi, male, age 34, electric welder, eye punctured by electric welding light, feared to light flowing tears, severe eye foreign body sensation, eye recovered normal after using the eyedrop three times.
Case 5, lie in, male, age 42, overuse of eyes, bloodred eyes, with the eye drop, one to two drops per eye, three times the eyes returned to normal.
It is to be understood that the described embodiments are merely individual embodiments of the invention, rather than all embodiments. All other implementations made by those skilled in the art without any inventive step based on the embodiments of the present invention belong to the protection scope of the present invention.
Claims (4)
1. An eye drop formulation characterized by: the formula comprises the following raw materials in parts by weight: 0.5-0.9 part of chloramphenicol, 0.2-0.3 part of naphazoline hydrochloride, 0.3-0.8 part of triamcinolone acetonide acetate and 7000-8000 parts of hertz functional water.
2. An ophthalmic formulation according to claim 1, wherein: the formula comprises the following raw materials in parts by weight: 0.7-0.9 part of chloramphenicol, 0.2-0.3 part of naphazoline hydrochloride, 0.4-0.6 part of triamcinolone acetonide acetate and 7000-7500 parts of hertz functional water.
3. An ophthalmic formulation according to claim 2, wherein: the formula comprises the following raw materials in parts by weight: 0.8 part of chloramphenicol, 0.25 part of naphazoline hydrochloride, 0.5 part of triamcinolone acetonide acetate and 7500 parts of Hertz functional water.
4. A method of making an eye drop comprising the formulation of claim 1, wherein: the method comprises the following steps: firstly, mixing the chloramphenicol and the naphazoline hydrochloride according to the formula ratio, adding the Hertz functional water, uniformly stirring, adding the triamcinolone acetonide acetate, fully and uniformly mixing, and packaging and sealing by using a high-temperature disinfection bottle for later use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010393483.1A CN111568925A (en) | 2020-05-11 | 2020-05-11 | Eye drop formula and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010393483.1A CN111568925A (en) | 2020-05-11 | 2020-05-11 | Eye drop formula and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111568925A true CN111568925A (en) | 2020-08-25 |
Family
ID=72117498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010393483.1A Withdrawn CN111568925A (en) | 2020-05-11 | 2020-05-11 | Eye drop formula and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111568925A (en) |
-
2020
- 2020-05-11 CN CN202010393483.1A patent/CN111568925A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109091675B (en) | Compound low-concentration atropine medicine eye drops and preparation method thereof | |
| CN107456440A (en) | A kind of low concentration atropic category medicament dropping ocular fluid and preparation method thereof | |
| CN107982212A (en) | A kind of atropic category medicament slow release eye drops and preparation method thereof | |
| CN103860625A (en) | Cranberry extract eye ophthalmic preparation and preparation method and uses thereof | |
| US7915312B2 (en) | Physiological method of improving vision | |
| CN102362924B (en) | Medicinal composition for treating ophthalmic diseases and preparation method thereof | |
| CN103040888A (en) | Ophthalmologic external preparation, as well as preparation method and application thereof | |
| CN114502155A (en) | Carbachol-brimonidine formulations for enhanced anti-presbyopia | |
| Deka et al. | Development, evaluation and characteristics of ophthalmic in situ gel system: a review | |
| CN111803441A (en) | Sodium hyaluronate eye drops containing 0.01% atropine and preparation method thereof | |
| Horng et al. | Improvement of presbyopia using a mixture of traditional chinese herbal medicines, including cassiae semen, wolfberry, and dendrobium huoshanense | |
| CN111568925A (en) | Eye drop formula and preparation method thereof | |
| CN100998863A (en) | N-acetyl carnosine eye drops for preventing and treating cataract and its preparation method | |
| CN102008488A (en) | Triamcinolone acetonide ophthalmic preparation and preparation method thereof | |
| CN109865016A (en) | A kind of pharmaceutical composition and its preparation method and application for treating xerophthalmia | |
| KR100963611B1 (en) | Eye composition comprising alginic acid based compounds and method of preparing the same | |
| Singh et al. | In vitro and in vivo evaluation of stimuli sensitive hydrogel for ophthalmic drug delivery | |
| EP3682867B1 (en) | Lutein-containing ophthalmic composition | |
| CN105963319A (en) | Saturated hydrogen saline water washing liquor and preparation method and application thereof | |
| CN112891326A (en) | Natamycin-loaded alginic acid gel medicine film and preparation method thereof | |
| CN102670851B (en) | Selenium-enriched traditional Chinese medicinal herb eye refreshing drops | |
| CN105832977A (en) | Eye-protecting nourishing solution and preparation method thereof | |
| Luo et al. | Case Report rhegmatogenous retinal detachment due to full-thickness macular hole secondary to uveitis: a case report | |
| CN1306938C (en) | Combination for local use for preventing anti treating ocular disease | |
| Chmielarz-Czarnocińska et al. | Ophthalmic applications of cyclopentolate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200825 |